| [1] Meel MH, Kaspers GJL, Hulleman E. Preclinical therapeutic targets in diffuse midline glioma[J]. Drug Resist Updat, 2019, 44:15-25.
[2] Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, Rutkowski S, Beilken A, Schmid I, Biassoni V, Gorelishev SK, Kramm C, Reinhard H, Schlegel PG, Kortmann RD, Reuter D, Bach F, Iznaga-Escobar NE, Bode U. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG):a phase Ⅲ clinical study[J]. J Neurooncol, 2019, 143:107-113.
[3] Mao Y, Yao Y, Zhang LW, Lu YC, Chen ZP, Zhang JM, Qi ST, You C, Wang RZ, Yang SY, Zhang X, Wang JS, Chen JX, Yang QY, Shen H, Li ZY, Wang X, Ma WB, Yang XJ, Zhen HN, Zhou LF. Does early postsurgical temo-zolomide plus concomitant radiochemotherapy regimen have any benefit in newly-diagnosed glioblastoma patients:a multi-center, randomized, parallel, open-label, phase Ⅱ clinical trial[J]? Chin Med J (Engl), 2015, 128:2751-2758.
[4] Wang Z, Jiang W, Pang QS, Wang P. Safety analysis of intensity-modulated radiation therapy of glioblastoma with simultaneous integrated boost technique[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2015, 24:431-433.[王政, 姜炜, 庞青松, 王平. 胶质母细胞瘤同期推量IMRT安全性分析[J]. 中华放射肿瘤学杂志, 2015, 24:431-433.]
[5] Chang SM, Wen PY, Vogelbaum MA, Macdonald DR, Bent MJ. Response assessment in neuro-oncology (RANO):more than imaging criteria for malignant glioma. Table 1[J]. Neurooncol Pract, 2015, 2:205-209.
[6] He P, Chen W, Qiu XX, Xi YB, Guan H, Xia J. A rare high-grade glioma with a histone H3 K27M mutation in the hypothalamus of an adult patient[J]. World Neurosurg, 2019, 128:527-531.
[7] Kleinschmidt-DeMasters BK, Mulcahy Levy JM. H3 K27M -mutant gliomas in adults vs. children share similar histological features and adverse prognosis[J]. Clin Neuropathol, 2018, 37:53-63.
[8] Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma:a randomized phase Ⅲ clinical trial[J]. J Clin Oncol, 2013, 31:4085-4091.
[9] National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Central Nervous System Cancers, Version 2[DB/OL]. 2019[2019-09-16]. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[10] Amelio D, Lorentini S, Schwarz M, Amichetti M. Intensity -modulated radiation therapy in newly diagnosed glioblastoma:a systematic review on clinical and technical issues[J]. Radiother Oncol, 2010, 97:361-369.
[11] Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy[J]. Nat Rev Cancer, 2004, 4:423-436.
[12] Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide[J]. Blood, 2005, 105:2862-2868.
[13] Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Phase Ⅰ trial of Pazopanib in patients with advanced cancer[J]. Clin Cancer Res, 2009, 15:4220-4227. |